However, treatment with tazemetostat, an EZH2 inhibitor that has recently been entered into the clinical treatment for epithelioid sarcoma [15], showed only a modest response rate in patients with relapsed or refractory BAP1-inactivated mutations [16]. Here, EZH2 is linked to epithelioid sarcoma.